124 results about "Levofloxacin" patented technology

The invention relates to a preparation method and application of a composite piezoelectric catalytic material NaNbO3-coated BiFeO3 for rapidly degrading antibiotics, NaNbO3 is flaky crystal grains with [001] crystallographic orientation prepared by a two-step molten salt method, and BiFeO3 is micro-nano particles prepared by a coprecipitation method. Composite micro-nano BiFeO3 powder and [001] oriented NaNbO3 flaky grains form a heterojunction, conversion of mechanical energy and electric energy of the material is achieved under the ultrasonic vibration condition, inductive charges are generated on the surface of the material, and photon-generated carriers move reversely under driving of a built-in electric field. According to the invention, the piezoelectric catalytic degradation capability of the BiFeO3 and NaNbO3 composite piezoelectric catalytic materials with different proportions on four antibiotics, namely oxytetracycline, levofloxacin, carbamazepine and paracetamol in different time periods is researched. When the mass ratio of the BiFeO3 to the NaNbO3 composite material is 1: 3, the oxytetracycline degradation rate within 30 min can reach 78.2%, the oxytetracycline degradation rate within 120 min can reach 91.8%, and the piezoelectric electro-catalysis characteristic is rapid and efficient. The method disclosed by the invention has important significance in developing a high-efficiency piezoelectric catalyst for degrading antibiotics.

The invention discloses a surface defect and oxygen doping co-modified pore-rich g-C3N4 nano material as well as preparation and application thereof. The preparation method comprises the following steps: mixing a white viscous melamine-cyanuric acid suspension with an oxalic acid solution to obtain a melamine-cyanuric acid-oxalic acid suspension solution, carrying out hydrothermal treatment to obtain a hydrogen bond connected self-assembled supramolecular aggregate, and finally carrying out thermal polycondensation on the self-assembled supramolecular aggregate and formaldehyde to obtain the surface defect and oxygen doping co-modified porous g-C3N4. The surface defect and oxygen doping co-modified g-C3N4 nano material with different morphologies and physicochemical properties is obtained. The preparation method is simple in process flow, efficient, low in cost and suitable for large-scale production, and the synthesis process meets the green chemical requirement; the obtained nano material has a higher specific surface area and more active sites, and has higher catalytic reaction and adsorption performance on organic pollutants, namely levofloxacin, ciprofloxacin and tetracycline hydrochloride, in a water body.

The invention relates to a method for detecting six second-line antituberculous drugs by high performance liquid chromatography. The method comprises the following steps: providing an internal standard stock solution and a standard stock solution of six second-line antituberculosis drugs; preparing an internal standard working solution and a standard curve working solution by utilizing the diluent; preparing a solution of a product to be detected by using the Tianlongitudinal sample extraction liquid TZ-002; a liquid chromatograph is used for detection, and the conditions are as follows: a mobile phase A is a Tianlongitudinal sample releasing agent TZ-D004; a mobile phase B is acetonitrile; a mobile phase C is water; and gradient elution. According to the method, the plasma concentration of the second-line antituberculous drug taken by a tuberculosis patient is measured by applying the reversed-phase high-performance liquid chromatography, the cost is relatively low, the analysis time is short, the sensitivity is high, and the accuracy is high. The kit can be used for simultaneously detecting the blood concentration of six second-line antituberculosis drugs such as isopropylthioamide, levofloxacin, linezolid, moxifloxacin, deramanib and bedaquiline in human serum, and is expected to provide a more reliable basis for clinicians to adjust the dosage of the antituberculosis drugs.

This invention belongs to the field of environmental chemical catalytic water treatment technology and discloses a method for preparing a Cu2O / black phosphorus catalyst for removing antibiotics from water. Using Cu2O and black phosphorus (BP) as precursor reactants, a series of Cu2O / BP composite photocatalysts were prepared. The BP catalyst was prepared by a simple hydrothermal method. Then, Cu(NO3)2·3H2O and BP were calcined in varying proportions to form the composite Cu2O / BP photocatalysts. Analysis revealed that the Cu2O was loaded onto the BP layer, forming a composite structure. The prepared catalysts were used to degrade levofloxacin hydrochloride under visible light, and the catalytic activity of the composite photocatalysts was evaluated. Results showed that among the photocatalysts with varying Cu2O / BP loadings, 3% and 4% Cu2O / BP exhibited the best photocatalytic degradation performance, achieving a degradation rate of 89% in 3 hours, 2.83 times that of pure BP. This demonstrates the successful preparation of highly efficient composite catalysts.

The invention discloses a blue fluorescent carbon dot as well as a preparation method and application thereof, and belongs to the technical field of drug monitoring. The carbon dot is a boron-nitrogen co-doped carbon dot, a carbon source is citric acid, a nitrogen source is p-phenylenediamine, and a dopant is boric acid; wherein the mass ratio of the citric acid to the boric acid to the p-phenylenediamine is (10-13): (12-15): (11-14). The preparation method comprises the following steps: mixing citric acid, boric acid and p-phenylenediamine, adding ethanol, carrying out ultrasonic treatment, heating at 150-200 DEG C for 20-60 minutes, cooling to room temperature, and purifying and drying supernate to obtain the blue fluorescent carbon dots. The blue fluorescent carbon dot provided by the invention is simple in preparation method, easily available in raw materials and suitable for industrial production, and the prepared fluorescent carbon dot can be used for drug monitoring of vancomycin and is also suitable for detecting ofloxacin and / or levofloxacin in food.

The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative. The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative thereof, for use in a method for the treatment of conjunctivitis and for the prevention or treatment of inflammation or prevention of infection after cataract surgery in a subject, according to a dosage regimen that improves patient compliance and tolerability and enables the prevention and treatment of intermediate / antibiotic-resistant infections.

According to the method, melamine and urea are used as carbon and nitrogen sources, hollow tubular phosphorus-doped carbon nitride is constructed by adopting a sodium polyphosphate-assisted hydrothermal-thermal polymerization method, molybdenum disulfide is loaded on the surface of P-TCN in a hydrothermal in-situ growth mode, and the hollow tubular phosphorus-doped heterojunction photocatalyst is obtained. The hollow tubular phosphorus-doped heterojunction photocatalyst P-TCN / MoS2 is prepared; the catalyst disclosed by the invention shows excellent degradation performance on ciprofloxacin, levofloxacin, rhodamine B and methylene blue under an illumination condition. The catalyst disclosed by the invention is simple in preparation method, low in cost and easily available in raw materials, and has a wide application prospect in the field of photocatalytic treatment of antibiotic and dye wastewater.

The invention discloses a Co3O4-Cu2-xS composite photo-thermal catalyst as well as a preparation method and application thereof. The composite photo-thermal catalyst is prepared by taking a surfactant as a bridge and compounding Co3O4 and Cu2-xS. The composite photo-thermal catalyst has a reduced band gap width, can effectively promote migration and separation of photon-generated carriers, enhances the absorption efficiency of visible light-near infrared light, and shows excellent photo-thermal conversion performance. The composite photo-thermal catalyst can be used for constructing a Co3O4-Cu2-xS + PMS + NIR catalytic system, and peroxymonosulfate is activated under the irradiation of near-infrared light so as to degrade antibiotics in water. Experiments prove that the Co3O4-Cu2-xS + PMS + NIR system disclosed by the invention can achieve the degradation rate of 99% on levofloxacin within 20 minutes, and the generation efficiency of active species is remarkably improved through the synergistic effect of a photothermal effect and interface activation. The catalyst has broad-spectrum degradation activity on various antibiotics, keeps efficient and stable catalytic performance in a wide pH range, and shows excellent ion interference resistance and adaptability to various water bodies.

The invention discloses a levofloxacin disinfection by-product as well as a preparation method and application thereof, belongs to the technical field of environmental chemistry and organic synthesis, and particularly relates to two levofloxacin disinfection by-products, namely a compound P352 and a compound P269. According to the method, a column chromatography gradient elution system is established by simulating reaction conditions of levofloxacin and sodium hypochlorite, and analysis instruments such as a high performance liquid chromatography-quadrupole-time-of-flight mass spectrometer, high performance liquid chromatography, carbon-13 nuclear magnetic resonance, hydrogen-1 nuclear magnetic resonance and a Fourier transform infrared instrument are combined, so that the content of levofloxacin in the levofloxacin is detected, and the content of levofloxacin in the levofloxacin is detected. And analyzing and identifying the structures and the purities of the compound P352 and the compound P269. The method can provide standard samples and technical support for the transformation mechanism, toxicity evaluation and pollution prevention and control of the levofloxacin disinfection by-product in the environment.

The utility model discloses a levofloxacin hydrochloride tablet preparation raw material quick mixing device, including frame, the frame top is provided with removal subassembly, the frame inside is provided with mixing box through removal subassembly, the both sides of mixing box are provided with guide component, and guide component is connected with the frame, the mixing box top is provided with drive assembly, the mixing box is provided with the pivot through drive assembly in the inside, the pivot is rotatably connected with mixing box, the pivot surface fixed mounting has the stirring rod. This kind of stirring and shaking combined mode can make raw materials flow and mix in multiple dimensions, can effectively avoid the situation that raw materials are not mixed sufficiently in local area, significantly improve the uniformity and effect of mixing, apply force to raw materials from different directions, speed up the mutual blending and diffusion between raw materials, can reach the ideal mixing state in shorter time, thereby improve the overall mixing efficiency, save production time.

The invention belongs to the technical field of environmental functional materials, and relates to a heterojunction photocatalyst as well as a preparation method and application thereof. The heterojunction photocatalyst is of a Z-type energy band structure and comprises beam-shaped h-BN and Ag3PO4 nano-particles loaded on the beam-shaped h-BN, and the particle size of the Ag3PO4 nano-particles ranges from 1 nm to 20 nm. According to the heterojunction photocatalyst, the initial degradation rate of levofloxacin hydrochloride in visible light within 60 min is larger than or equal to 88%, and the degradation rate is kept to be 80% or above after four times of circulation.

The application belongs to the technical field of electroluminescence, and particularly relates to a preparation method of a high-entropy oxide material and application of the high-entropy oxide material in electrochemiluminescence detection of levofloxacin. The high-entropy oxide material is a kind of five-element high-entropy oxide HEO-800 material with simple raw materials, convenient synthesis, excellent electrochemiluminescence performance, which is synthesized by taking metal nitrate of Fe, Co, Cu, Zn and Ni as raw materials, and taking Na2CO3 and NaOH as raw materials. The HEO-800 material has excellent conductivity and chemical stability, and a multi-electron reaction potential accelerates the conversion of dissolved oxygen into reactive oxygen species (ROS), enhances the electroluminescence intensity, and based on the quenching effect of LVX, a method for detecting LVX by using a luminol / HEO-800 system is established. By fitting the change of ECL intensity with the concentration of LVX, a linear calibration curve is obtained, the correlation coefficient is 0.993, and the detection limit is 1.02*10 ‑5 μM (S / N=3). The material has good sensitivity, stability and reproducibility for electrochemiluminescence detection of LVX, and provides a new scheme for designing a new electrocatalyst for testing LVX.

The invention belongs to the technical field of adsorption materials, and discloses a hydrothermal carbon loaded cuprous oxide adsorbent as well as a preparation method and application thereof. The preparation method of the hydrothermal carbon loaded cuprous oxide adsorbent comprises the following steps: (1) mixing corn straw powder with a solvent, and carrying out hydrothermal reaction to prepare hydrothermal carbon; and (2) mixing the hydrothermal carbon, copper chloride, sodium dodecyl benzene sulfonate and alkali liquor, and carrying out heating reaction to prepare the hydrothermal carbon loaded cuprous oxide adsorbent. The adsorption mechanism of the hydrothermal carbon loaded cuprous oxide adsorbent is that efficient adsorption of fluoroquinolone antibiotic levofloxacin or tetracyclines is realized through electrostatic interaction, pi-pi accumulation, hydrogen bonds, pore filling and hydrophobic interaction.

The application discloses a flagellum inhibiting peptide of pseudomonas aeruginosa and a preparation method and application thereof, and the sequence of the flagellum inhibiting peptide is Lys-Ile-Gly-Leu-Phe-Arg-Trp-Arg. The synthetic inhibiting peptide has a time-dependent self-assembly ability, can gradually evolve from scattered granular into filamentous structure, and finally forms a stable net-like morphology. The synthetic inhibiting peptide can significantly inhibit the flagellum motility of PAO1 and other strains of pseudomonas aeruginosa, and has synergistic antibacterial activity when combined with allicin, ciprofloxacin, meropenem, levofloxacin, polymyxin B and the like. Moreover, the synthetic inhibiting peptide has obvious bacteriostatic and healing-promoting effects on burn wound infection.

The invention discloses a GSH (glutathione) response type nano-drug carrier as well as a preparation method and application thereof, the nano-drug carrier is a levofloxacin loaded BSA (bovine serum albumin) and PAMAM (polyamidoamine) compound, and is obtained by coupling BSA to a levofloxacin loaded PAMAM nano-drug by a disulfide bond-containing compound; the invention further discloses application of the levofloxacin loaded BSA and PAMAM compound in an antibiotic controlled release drug delivery system. According to the present invention, the drug can be effectively sealed, the non-specific release of the drug under the normal physiological condition can be prevented, the controllable release of the drug can be initiated in the presence of the GSH, the on-demand drug delivery can be achieved, and the drug delivery scheme can be optimized;

The invention discloses a medical dressing capable of absorbing moisture and releasing sweat and a preparation method of the medical dressing, and relates to the technical field of medical dressings, the medical dressing comprises a polyurethane copolyester nanofiber membrane, and the preparation method of the polyurethane copolyester nanofiber membrane comprises the following steps: pouring non-isocyanate polyurethane copolyester, levofloxacin and polyacrylonitrile into hexafluoroisopropanol, and stirring uniformly; carrying out electrostatic spinning; and spin-coating a chitosan-gelatin-glycerol mixed solution, and spin-coating a spermidine cross-linking agent to obtain the polyurethane copolyester nanofiber membrane. By introducing the polyglycolic acid-based non-isocyanate polyurethane copolyester and the levofloxacin, the levofloxacin is uniformly dispersed and embedded into a fiber network, so that uniform dispersion and controllable release of an antibacterial drug are realized, growth and reproduction of bacteria at a wound are effectively inhibited, and the problems of wound infection and slow healing are solved; the healing speed is increased; and the complication risk is reduced.

The invention belongs to the technical field of coordination polymers, and particularly relates to a zinc coordination polymer as well as a preparation method and application thereof in fluoroquinolone antibiotic detection. The structural formula of the zinc coordination polymer is [Zn (mu3-L ') (H2O)] n, wherein L' 2-is generated by hydrolyzing 5-((4 '-cyanobenzyl) oxygen) isophthalic acid (H2L) in the reaction process. The zinc coordination polymer is prepared by the following steps: adding Zn (NO3) 2.6 H2O and 5-((4 '-cyanobenzyl) oxygen) isophthalic acid into a mixed solvent containing acetonitrile and water, and carrying out solvothermal reaction. The zinc coordination polymer has a one-dimensional structure, has good fluorescence selectivity detection performance on fluoroquinolone antibiotics in an aqueous solution, such as ofloxacin, levofloxacin and norfloxacin, and can be used as a fluorescence sensor for efficiently detecting the fluoroquinolone antibiotics.

The invention discloses a preparation and purification process of lactic acid levofloxacin, and relates to the technical field of medical chemistry. The preparation and purification process comprises the following steps: by taking a compound a as an initial raw material, racemizing under the action of a catalyst to obtain a compound b, reacting the compound b with lactic anhydride to obtain a compound d, namely a levofloxacin lactate crude product, and purifying to obtain the levofloxacin lactate. And crystallizing the compound d levofloxacin lactate crude product through a mixed solvent of an acetate solvent and water to obtain a compound d levofloxacin lactate finished product. The catalyst is a chiral ionic catalyst, has the advantages of good activity, high efficiency and the like, can effectively promote the reaction, and can improve the yield and purity of the product through crystallization of a mixed solvent of an acetic ester solvent and water.

The invention provides a characteristic gene combination for predicting the drug sensitive phenotype of stenotrophomonas maltophilia to levofloxacin and compound sulfamethoxamine. The characteristic gene combination for predicting the drug sensitive phenotype of stenotrophomonas maltophilia to levofloxacin comprises parC: 254 (G-gt; a), ParC: 259 (A-gt; c), ParC: 260 (G-gt; t), gyrA: 248 (A-gt; t), smT: 12 (G-gt; t) and the like; the characteristic genes of the drug sensitivity phenotype of the compound sulfamethoxazole include sul1, sul2, Gsh2: 1076 (C-gt; g), smT: 12 (G-gt; t), cysJ: 445 (C-gt; a), 14242002, etc. According to the characteristic gene combination obtained through screening, the drug sensitivity phenotype prediction result of stenotrophomonas maltophilia levofloxacin and compound sulfamethoxamine is greatly shortened.

The invention relates to a fumaric acid metal organic framework for treating eye germ infection and application of the fumaric acid metal organic framework in treating eye germ infection. The fumaric acid metal organic framework is Zr / Fe-coated FA MOFs, metal coordination ions are Zr (IV) and Fe (III), and a ligand is fumaric acid. The Zr / Fe-coated FA MOFs has excellent anti-biofilm activity, and the effect of the Zr / Fe-coated FA MOFs can be greatly improved when the Zr / Fe-coated FA MOFs is combined with levofloxacin; besides, the invention further provides a packaged microneedle system Zr / Fe-FA MNs, MOFs can be directly delivered to a bacterial microcolony focus area in a 3D limited microenvironment through the precise penetrating capacity of a microneedle, and the effectiveness of the medicine in biological membrane eradication is remarkably enhanced. Zr / Fe-coated FA MNs not only can overcome the limitation of traditional eye drops in the aspect of cornea permeability, but also can realize long-acting treatment through the sustained release characteristic of MOFs and the sustained release characteristic of microneedles.

The invention discloses a levofloxacin sodium chloride injection and a preparation method thereof. The injection contains levofloxacin, curcumin, disodium lauryl sulfosuccinate, sodium chloride and hydrochloric acid. The preparation method comprises the steps of metal container pretreatment, liquid medicine preparation, liquid medicine filtration, liquid medicine sterilization and liquid medicine filling. According to the present invention, the curcumin is adopted as the light absorption agent so as to effectively avoid the degradation of the levofloxacin under the illumination condition, such that the stability of the preparation is improved, and the tetrasodium glutamate diacetate is adopted as the metal ion chelating agent to pre-treat the metal container in the preparation process; the stability of the levofloxacin sodium chloride injection preserved in a metal container for a long time can be improved.

The present invention relates to a fumarate metal-organic framework for treating ocular bacterial infections, and also relates to its use in treating ocular bacterial infections. The fumarate metal-organic framework is Zr / Fe@FA MOFs, the metal coordination ions are Zr(IV) and Fe(III), and the ligand is fumaric acid. The Zr / Fe@FA MOFs have excellent anti-biofilm activity, and their effect can be greatly improved when used in combination with levofloxacin. In addition, the present invention also provides an encapsulated microneedle system, Zr / Fe@FA MNs, which can deliver MOFs directly to bacterial microcolony lesion areas in 3D confined microenvironments through the precise penetration ability of microneedles, significantly enhancing the effectiveness of drugs in biofilm eradication. Zr / Fe@FA MNs can not only overcome the limitations of traditional eye drops in corneal permeability, but also achieve long-term treatment through the sustained release of MOFs and the slow-release properties of microneedles.

This invention discloses a method and application for preparing metal-doped composite catalysts based on ZIF-67, relating to the field of wastewater treatment technology. This invention constructs a multi-component synergistic system through the coordination of functional groups on the surface of biochar with ZIF-67 and the electronic coupling effect between rare earth metals and Co. Compared with traditional pure chemical support synthesis methods, this reduces costs and improves environmental compatibility. The metal-doped composite catalyst prepared by this invention is a novel heterogeneous catalyst. Through the electrostatic interaction between the biochar support and Co ions, and the metal-metal bonds formed between La / Ce and Co, it significantly enhances the stability of Co ions, effectively avoiding secondary pollution. The metal-doped composite catalyst prepared by this invention can efficiently activate persulfate to generate reactive oxygen species and synergistically remove multiple pollutants from complex water bodies containing sulfamethoxazole, tetracycline, levofloxacin, and other antibiotics such as methylene blue.

The utility model provides a heating device for synthesizing fosfomycin levofosfomycin amine salt, and particularly relates to the technical field of pharmaceutical production, the heating device comprises a plurality of monomer tanks with fan-shaped cross sections, the end parts of the monomer tanks are sealed by sealing plates, and the upper ends and the lower ends of the monomer tanks are respectively provided with inlets and outlets; the single tanks are annularly arranged at equal intervals, and an electric heating plate is arranged between every two adjacent single tanks. The electric heating plates are arranged between the single tanks, so that the heating distance between a heat source and materials is reduced, the heating area is increased, and the heating efficiency can be further improved.

The utility model provides a granulator for processing levofloxacin hydrochloride tablets, which comprises a bottom plate, support plates are respectively arranged on the front side and the rear side of the top of the bottom plate, an inclined mechanism is arranged between the two support plates, the inclined mechanism comprises an inclined plate arranged between the two support plates, a plurality of material guide plates are arranged on the inclined plate, and the material guide plates are arranged on the inclined plate. A granulating mechanism is arranged on the left sides of the tops of the two supporting plates. According to the granulator for processing the levofloxacin hydrochloride tablets, disclosed by the utility model, not only can materials be basically produced and granulated, but also the materials can roll through the inclined material guide plate, and the blanking speed of the materials is slowed down under the action of the baffle plate on the inclined material guide plate, so that the drying effect of the materials is better; the situation that hot air is not blown to the face, making contact with the conveying belt, of the materials is avoided, workers are prevented from conducting secondary drying on the materials, time and labor are saved, the production efficiency is improved, and the use requirements of people are met.

The application relates to the technical field of compound preparation, and discloses a synthesis method of fosfomycin intermediate levofosfoxacin salt, which comprises the following steps: taking propynol as raw material, performing esterification reaction, adding Pt / C, Cu (II) EDTA and hydrogen into the obtained reaction solution to prepare a cis-propenyl dichloro oxygen phosphorus solution, adjusting the pH of the reaction solution by using ammonia gas after hydrolysis, and performing salt reaction and epoxidation by using R- (+) -alpha-phenylethylamine to obtain the product after post-treatment. The propynol is not hydrolyzed after esterification, so that the impurity propadienyl phosphate is reduced; the later hydrogenation can obtain higher-purity cis-propenyl phosphate; the step of hydrolysis after esterification is reduced, a large amount of water does not need to be distilled and concentrated, and energy consumption is reduced; the reaction temperature and hydrogen pressure in the hydrogenation step are both low, and the reaction safety is high; R- (+) -alpha-phenylethylamine is used in the epoxidation stage, so that the splitting operation is not needed, and the process is simplified; the solvents can be recycled and reused, and the method is environment-friendly.

The invention provides a method for improving the purity of a levofloxacin product, which comprises the following steps: carrying out condensation reaction on levofloxacin carboxylic acid, dimethyl sulfoxide and N-methyl piperazine, adding water into the obtained concentrate, adding a specific acidic reagent to adjust the pH value of the system to 1.0-4.5, heating to dissolve, cooling to separate out impurities, filtering, adding trichloromethane into the filtrate, extracting under the condition that the pH value is 7.0-7.5, and filtering to obtain the levofloxacin product. And collecting an organic phase, concentrating, adding ethanol, and crystallizing to obtain a high-purity levofloxacin product. According to the method, by limiting the raw material ratio, the process conditions and the specific acid reagent, generation of an isomeride impurity I is reduced from the reaction source, efficient separation of the impurity I and the levofloxacin is achieved, the content of the isomeride impurity I in the levofloxacin product is remarkably reduced, and the purity of the levofloxacin product is improved. Meanwhile, other insoluble impurities under the acidic condition are removed through filtration, so that a high-purity product with the purity of 99.86% or above is obtained. The whole impurity removal process is simple, efficient, safe, environment-friendly and especially suitable for large-scale industrial production.

A method for degrading levofloxacin in wastewater based on a visible light-driven CMP (Chemical Molecular Polymer) photocatalytic system is disclosed. This invention aims to address the problems of most existing photocatalysts being only responsive to ultraviolet light, having limited solar energy utilization efficiency, being highly susceptible to the influence of wastewater turbidity and color, and exhibiting low degradation efficiency for norfloxacin. The method comprises: 1. Synthesizing a conjugated microporous polymer; 2. Performing photocatalytic degradation under visible light irradiation. This invention aims to achieve efficient solar energy utilization by utilizing the excellent photogenerated charge generation and transport efficiency of conjugated microporous polymers for the efficient degradation of levofloxacin. This provides a mild, efficient, and environmentally friendly green method for degrading the novel pollutant levofloxacin, offering a new option for treating complex industrial wastewater.

The invention relates to a pH responsive hydrogel drug delivery system for corneal neovascularization treatment, which is a composite hydrogel LEV-DG-HPMC formed by forming LEV-DG nano-micelles from drugs levofloxacin and dipotassium glycyrrhizinate by a film dispersion method, then heating and self-assembling to form LEV-DG hydrogel, and introducing hydroxypropyl methylcellulose as a tackifier. The drug delivery system disclosed by the invention has unique pH response characteristics, can accurately identify the alkali burn microenvironment and control the release of drugs, and obviously prolongs the cornea residence time. Through the synergistic effect of DG and LEV, the vicious circle of infection-inflammation-neovascularization is effectively blocked. Experiments show that the system can significantly reduce the corneal neovascularization area and accelerate epithelium repair, has good biocompatibility and treatment effect, and provides a new solution for treatment of corneal alkali burn.